Previous 10 | Next 10 |
home / stock / hlukf / hlukf news
The following slide deck was published by H. Lundbeck A/S in conjunction with their 2021 Q1 earnings call. For further details see: H. Lundbeck A/S 2021 Q1 - Results - Earnings Call Presentation
H. Lundbeck A/S (HLUKF) Q4 2020 Earnings Conference Call February 04, 2021 07:00 AM ET Company Participants Deborah Dunsire - President & Chief Executive Officer Anders Götzsche - Executive Vice President & Chief Financial Officer Johan Luthman - Executive Vice President, Researc...
The following slide deck was published by H. Lundbeck A/S in conjunction with their 2020 Q4 earnings call. For further details see: H. Lundbeck A/S 2020 Q4 - Results - Earnings Call Presentation
H. Lundbeck A/S (HLUKF): FY Non-GAAP EPS of DKK18.91; GAAP EPS of DKK7.95.Revenue of DKK17.67B (+3.7% Y/Y)Press Release For further details see: H. Lundbeck A/S reports FY results
Health Canada approves Lundbeck's (HLUKF) Vyepti (eptinezumab) for the preventive treatment of migraine in adults who have at least 4 migraine days per month, making it the first Health Canada-approved intravenous ((IV)) treatment for migraine prevention.Vyepti is a humanized monoclonal ...
The following slide deck was published by H. Lundbeck A/S in conjunction with their 2020 Q3 earnings call. For further details see: H. Lundbeck A/S 2020 Q3 - Results - Earnings Call Presentation
H Lundbeck A/S (HLUKF) Q3 2020 Earnings Conference Call November 03, 2020, 07:00 ET Company Participants Deborah Dunsire - President & CEO Johan Luthman - EVP of R&D Anders Götzsche - EVP & CFO Peter Anastasiou - EVP, North America Conference Call Participants Wimal Kapadia -...
COPENHAGEN, Denmark , Aug. 31, 2020 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced headline results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study [i] that assessed the efficacy and tolerability of Vyepti when initiated during a migrain...
H. Lundbeck A/S (HLUKF) Q2 2020 Results Earnings Conference Call August 13, 2020, 07:00 AM ET Company Participants Deborah Dunsire - President and Chief Executive Officer Johan Luthman - Executive Vice President, R&D Anders Gotzsche - Executive Vice President and Chief Financ...
The following slide deck was published by H. Lundbeck A/S in conjunction with their 2020 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
H Lundbeck A/S Company Name:
HLUKF Stock Symbol:
OTCMKTS Market:
COPENHAGEN, Denmark , Aug. 31, 2020 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced headline results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study [i] that assessed the efficacy and tolerability of Vyepti when initiated during a migrain...
Health Canada Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment of Major Depressive Disorder Canada NewsWire MONTREAL, Feb. 22, 2019 MONTREAL , Feb. 22, 2019 /CNW Telbec/ - Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Can...